DKSH Management Ltd.
/ Key word(s): Acquisition
DKSH has signed an agreement to acquire two pharma brands from Eisai for nine markets in Asia Pacific. The acquisition fits in DKSH's strategy to grow in higher value-added segments and services and solidifies DKSH Healthcare's leading position in the region.
Zurich, Switzerland, November 7, 2022 - DKSH has signed an agreement to purchase two well-known pharma brands, Myonal and Merislon, from Eisai in Thailand, Indonesia, the Philippines (Myonal only), Malaysia, Singapore, Taiwan (Merislon only), Myanmar, Cambodia, and Laos. Myonal is a muscle-relaxant which is used to treat neck-shoulder-arm syndrome and Merislon is approved to treat vertigo and dizziness associated with inner-ear disorders. Both brands are recognized among medical professionals in Asia Pacific and have established safety profiles.
For more information please contact:
End of Media Release
|Company:||DKSH Management Ltd.|
|Phone:||044 386 72 72|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||1480087|
|End of News||EQS News Service|
1480087 07.11.2022 CET/CEST